Shan Yuan, M.D.

- Transfusion Medicine
- Clinical Professor, Department of Pathology
- Medical Director, Blood Bank and Transfusion Services
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
American Board of Pathology, Blood Banking/Transfusion Medicine
American Board of Pathology, Clinical Pathology
Unrestricted Medical License, State of California
United States Medical Licensing Examination
1996-2000, Doctor of Medicine, Duke University School of Medicine, Durham, NC
1992 –1996, Bachelor of Arts, Biology, Oberlin College, Oberlin, OH
2004 –2005, Fellow, Transfusion Medicine, Puget Sound Blood Center and University of Washington Medical Center, Seattle, WA
2000 –2004, Chief Resident, Laboratory Medicine (2003-2004), Resident, Anatomic Pathology and Laboratory Medicine, University of Washington Medical Center, Seattle, WA
2012 - present, Associate Clinical Professor, Department of Pathology, City of Hope, Duarte, CA
2007 - 2012, Associate Medical Director of Transfusion Medicine, Assistant Professor, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
2005 - 2007, Staff Physician, Transfusion Medicine, City of Hope, Duarte, CA
Awards & Memberships
Awards
2010-2011, Faramarz Naeim Faculty Teaching Award for Clinical Pathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA
2004, Paul E. Strandjord Young Investigator Award, 39th Annual Meeting of the Academy of Clinical Physicians and Scientists
2003, Strandjord-Clayson Research Award, Department of Laboratory Medicine, University of Washington Medical Center
2003, Paul E. Strandjord Young Investigator Award, 38th Annual Meeting of the Academy of Clinical Physicians and Scientists
Memberships
American Association of Blood Banks
California Blood Bank Society
American Society of Hematology
Publications
- Zhuang L, Woo J, Francisco F, Bertram R., Wang S, Jackson R., Yuan S. Clotted apheresis hematopoietic stem cell product. Journal of Clinical Apheresis. 2024. Published online December 05,2024. https://onlinelibrary.wiley.com/doi/10.1002/jca.70002
- Yuan S, Chang S, Kim H, Wang S. Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients. Transfusion. 2024; 64:2332-2340.
- Zhuang L, Shan H, Yang D, Woo J, Wang S, Jackson R, Yuan S. Use of half RBC units in oncology patients during severe shortages to extend hospital supply" Transfusion, 2024;64:1909-1918.
- Woo JS, Zhuang L, Jackson R, Wang S, Agrawal V, Blackmon A, Pourhassan H, Yuan S. Clinical management of a patient following a granulocyte transfusion from a donor positive for COVID-19. Lab Med. 2024; 55:524-527.
- Yuan S, Yang DY, Nakamura R, Al Malki MM, Salhotra A, Afkhami M, Wang S. Lack of RBC transfusion independence by day 30 following allogeneic hematopoietic stem cell transplant strongly predicts inferior survival and high non-relapse mortality in acute myeloid leukemia patients. Transfusion. 2024;64:255-280.
- Salhotra A, Yuan S, Ali H. Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation. Front Oncol. 2023;13:1196564. Published 2023 Aug 28. doi:10.3389/fonc.2023.1196564 (Co-first author).
- Zhuang L, Lauro D, Wang S, Yuan S. Addition of plerixafor in poorly mobilized allogeneic stem cell donors. J Clin Apher. 2022; 37:388-394.
- Yuan S, Otrock ZK. Platelet transfusion: An update on indications and guidelines. Clin Lab Med. 2021;41:621-634.
- Yuan S, Yang DY, Nakamura R, Zhuang L, Al Malki MM, Karanes C, Wang S. RBC and platelet transfusion requirements in the first 30 and 100 days after allogeneic hematopoietic cell transplantation and transfusion independence. Transfusion 2020;60:2225-2242.
- Zhuang L, Boriboonnangkul P, Wang S, Yuan S. Third time’s a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor. Transfusion 2020;60:1253-1259